Login
$KRRO
$12.71 -$0.90 (6.61%) Live

$KRRO 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Termination of a Material Definitive Agreement; Results of Operations and Financial Condition

Ended third quarter 2026 with $124.8 million in cash, cash equivalents and marketable securities, supporting a cash runway into the second half of 2028

22 Oct 2026 8-K: Other Events

Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency

05 Oct 2026 8-K: Other Events

Initiated a Phase 1/2 clinical trial to enroll healthy volunteers and patients with Urea Cycle Disorders of any mutational background

19 Aug 2026 8-K: Other Events

On August 19, 2026, Korro Bio, Inc., or Korro, announced a submission to the Australian Alfred Health Human Ethics Committee to initiate a first-in-human Phase 1/2 clinical trial for KRRO-121, a GalNAc-conjugated RNA editing oligonucleot...

06 Aug 2026 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more

KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical trial in second half of 2026

11 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

The following is a summary of the matters voted on at the 2026 annual meeting of stockholders of Korro Bio, Inc., or Korro, held on June 10, 2026, or the Annual Meeting.

19 May 2026 8-K: Other Events

Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

07 May 2026 8-K: Results of Operations and Financial Condition

Hosted virtual Analyst Day showcasing lead program KRRO-121’s potential to be a first-in-class transformational treatment for hyperammonemia in patients with urea cycle disorders (UCDs) and hepatic encephalopathy (HE); regulatory filing ...

12 Mar 2026 8-K: Results of Operations and Financial Condition

Nominated KRRO-121 development candidate for the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy

09 Mar 2026 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more

This Subscription Agreement (this “Agreement”) is made and entered into as of March 9, 2026 (the “Effective Date”) by and among Korro Bio, Inc., a Delaware corporation (the “Company”), and each of the purchasers listed on the signature p...

27 Jan 2026 8-K: Other Events

KRRO-121: A Potential First-in-Class Treatment for Ammonia Control January 27th, 2026 Exhibit 99.1

15 Jan 2026 8-K: Other Events

Forward-Looking Statement and Disclaimers Forward-Looking Statements Certain statements in this presentation may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amend...

18 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation

This Amended and Restated Employment Agreement (“Agreement”) is made between Korro Bio, Inc., a Delaware corporation (“Parent”, and together with its subsidiaries, including Korro Bio Ops, Inc., the “Company”), and Jeffrey Cerio (the “Ex...

12 Nov 2025 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more

KRRO-110 produced functional protein in Alpha-1 Antitrypsin Deficiency (AATD) patients

08 Oct 2025 8-K: Departure/Election of Directors or Officers; Compensation

This Separation Agreement (“Agreement”) is made between Korro Bio, Inc., a Delaware corporation (“Parent”, and together with its subsidiaries, including Korro Bio Ops, Inc., the “Company”), and Vineet Agarwal (the “Executive”). The Compa...

12 Aug 2025 8-K: Results of Operations and Financial Condition

Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 on track for the second half of 2025

11 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

The following is a summary of the matters voted on at the 2025 annual meeting of stockholders of Korro Bio, Inc., or Korro, held on June 11, 2025, or the Annual Meeting.

07 May 2025 8-K: Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities

Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD) on track for the second half of 2025

27 Mar 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

18 Mar 2025 8-K: Results of Operations and Financial Condition

Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim readout expected in the second half of 2025

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support